Trelegy Ellipta® 100 mcg (fluticasone furoate, umeclidinium, and vilanterol) is a once-daily prescription medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three medications—fluticasone furoate (a corticosteroid), umeclidinium (a long-acting muscarinic antagonist, or LAMA), and vilanterol (a long-acting beta-agonist, or LABA)—in a single inhaler. Together, these ingredients work to improve lung function, reduce airway inflammation, and help prevent COPD flare-ups and symptoms such as shortness of breath, wheezing, and coughing.

Features:

• Triple-Combination Therapy: Trelegy Ellipta® contains fluticasone furoate, umeclidinium, and vilanterol, each targeting a different aspect of COPD. This combination offers a more comprehensive treatment approach to manage COPD symptoms.

• FDA-Approved: Approved by the FDA for the maintenance treatment of COPD in adults.

• Once-Daily Dosing: Trelegy Ellipta® is taken once daily with one inhalation, providing 24-hour relief from symptoms and reducing the risk of exacerbations.

• Proven Effectiveness: Clinical studies have shown that Trelegy Ellipta® significantly improves lung function, reduces COPD flare-ups, and helps manage daily symptoms such as wheezing, coughing, and shortness of breath.